Voyager Therapeutics
64 Sidney Street
Cambridge
Massachusetts
02139
United States
Website: http://www.voyagertherapeutics.com/
188 articles about Voyager Therapeutics
-
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
4/22/2024
Voyager Therapeutics, Inc. announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene therapy programs across 12 oral and poster presentations at the upcoming American Society of Gene & Cell Therapy’s 27th annual meeting taking place in Baltimore, May 7-11.
-
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
4/16/2024
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases.
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 26, 2024
3/26/2024
Voyager Therapeutics, Inc. provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into employment with Voyager.
-
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
3/13/2024
Voyager Therapeutics, Inc. today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024.
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2/28/2024
Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, reported fourth quarter and full year 2023 financial and operating results.
-
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
2/26/2024
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program.
-
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
2/21/2024
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024.
-
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
2/20/2024
Voyager Therapeutics, Inc. announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease.
-
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
2/7/2024
Voyager Therapeutics, Inc. today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20 a.m. ET.
-
Voyager Therapeutics Announces Pricing of Public Offering - Jan 05, 2024
1/5/2024
Voyager Therapeutics, Inc. announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share.
-
Voyager Therapeutics Announces Proposed Public Offering - Jan 04, 2024
1/4/2024
Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.
-
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Voyager Therapeutics, Inc. announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024, at 9:45 a.m. PT.
-
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
1/2/2024
Voyager Therapeutics, Inc. today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
-
The Swiss pharma is looking to leverage Voyager Therapeutics’ capsid technology for gene therapies aimed at treating Huntington’s disease and spinal muscular atrophy.
-
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program- IND filing expected in mid-2025 -
12/6/2023
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program.
-
To protect the central nervous system, the blood-brain barrier bars entry to around 98% of molecules—but approaches like Roche’s trontinemab could spell new hope in Alzheimer’s and beyond.
-
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
11/6/2023
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2023 financial and operating results.
-
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
10/30/2023
Voyager Therapeutics, Inc. today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023.
-
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
9/25/2023
Voyager Therapeutics, Inc. today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan 7th Annual Genetic Medicines Conference in New York, NY, on October 2, 2023, at 5:30 p.m. ET.
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 07, 2023
9/7/2023
Voyager Therapeutics, Inc. has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.